Amy Calistri
Stock of the Month
Stephen Leeb
Income Performance Report
Roger Conrad
The Utility Forecaster
Paul McWilliams
Next Inning

Apple: A value stock?


Bookmark and Share
by J. Royden Ward, editor Cabot Benjamin Graham Value Letter

J. Royden WardApple (AAPL) has a unique ability to identify what customers want, produce easy-to-use products, and launch unique marketing campaigns to create demand.

The company’s revolutionary iPod digital music player, iTune online music store, and iPhone helped sales to increase 33% per year during the past five years, while earnings per share surged 70% per year during the same period.

Sales soared 66% and EPS catapulted 83% during the past 12 months, aided by the success of Apple’s iPad tablet computer.

In addition to gaining market share in the computer, smart phone and tablet sectors, new product launches, such as the iPhone 4S, will keep Apple ahead of the competition.
Advertisement
Banner


The death of Steve Jobs, co-founder of Apple, is upsetting; Mr. Jobs will be missed. But the company’s strong management team and innovative spirit will continue to thrive.

Apple’s sales and earnings slowed a tad during the quarter ended 9/30/11, because smart phone buyers held off new purchases until the new iPhone 4S was launched on October 14.

Consumers gobbled up four million new iPhone 4S smart phones during the first weekend, a record for any phone!

The highly successful launch will lead to record sales and profits in the current quarter ending 12/31/11 and will send AAPL’s stock price to a new high (426.70) within the next two months.

We expect Apple’s earnings to grow at a rapid 22% pace during the next five years. At 11.6 times our one-year forward EPS estimate of 33.00, AAPL shares are clearly undervalued.

The development of exciting new products portends continued rapid growth in future years.

AAPL shares will likely advance to our Minimum Sell Price of 655.71 within the next two to three years. We consider AAPL to be a very low risk investment.

Learn more about this financial newsletter at J. Royden Ward's Cabot Benjamin Graham Value Letter.

Banner
News Flash

Linkedin: Professional profits
by Leo Fasciocco, editor Ticker Tape Digest

Online professional network operator Linkedin (LNKD) recently moved above its technical breakout point of $108.53. We now target a move to $138.


Read more...

 

Tap in to water stocks
by Doug Fabian, editor Making Money Alert

As we prepare for the summer heat, water presents a significant investment opportunity -- especially as states such as California and Texas face droughts. The PowerShares Water Resource ETF (PHO) presents one way to invest in water's untapped potential.


Read more...


   

Pax World: High yield exception
by Amy Calistri, editor The Daily Paycheck

I generally prefer closed-end or exchange-traded funds because the fees tend to be lower. But I made a special case for Pax World High Yield Bond (PAXHX); this high-yield bond fund is my only open-ended mutual fund holding.


Read more...

 

Amgen: Biotech DRIP
by Chuck Carlson, editor DRIP Investor

Amgen (AMGN) is one of the oldest and largest players in the biotechnology area. It pioneered the development of products based on advances in recombinant DNA and molecular biology, launching the biotechnology industry’s first blockbuster medicines.


Read more...

 

Fidelity fund expert looks to Japan
by Jim Lowell, editor Fidelity Investor

In my May Marketwatch investment strategy column I noted, “Set against the backdrop of having already been thrown out with the Eurozone’s bathwater, I like Japan’s marketplace overall and, more specifically, their small cap marketplace which caters to domestic counter traffic.”


Read more...

 

MOO: Market Vectors Agribusiness
by Doug Fabian, editor Making Money Alert

Everyone needs food to survive, so wouldn't it be great to make money from it? We can. The global agriculture business provides a fairly stable investment with growth potential. In particular, I am looking at Market Vectors Agribusiness ETF (MOO).


Read more...

 

Celgene: Selloff creates opportunity
by J. Royden Ward, editor Cabot Benjamin Graham Value Letter

Celgene (CELG) develops and assists in the marketing of drugs to treat cancer and infl ammatory diseases. It acquired several companies recently, which will expand its product line and add promising products in various stages of development.


Read more...

 

Senior housing reits for income
by Brian Hicks, editor Wealth Advisory

Omega Healthcare Investors (OHI) and Medical Properties Trust (MPW) caters to the senior housing/assisted living facilities. Given the growing senior population, it makes sense to be somewhat over-exposed to companies that target this market.


Read more...

 

Buffett: Still banking on banks
by Ron Rowland, editor All Star Investor

Wise investors zero in on conflicting data points. Warren Buffett, the wisest investor of all, provided plenty to consider at the Berkshire Hathaway annual meeting. 


Read more...

 

Questcor: 'Exponential demand'
by Dennis Slothower, editor Stealth Stocks

Questcor Pharmaceuticals (QCOR), our latest featured stock of the month, is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.


Read more...

 



Banner



Close
Select Offer: Schwab Options Market Commentary